

ICMJE DISCLOSURE FORM

Date: 26/10/2026

Your Name: Pablo Corral

Manuscript Title: Edición génica in vivo de PCSK9 en la prevención cardiovascular aterosclerótica: de la validación genética a la clínica

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i5.21056>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td>Click the tab key to add additional rows.</td></tr> </table>							Click the tab key to add additional rows.
	Click the tab key to add additional rows.								
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%;"> <tr><td>Novartis</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Novartis					
Novartis									
3	Royalties or licenses	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<div> ☒ None </div> <table border="1"> <tr><td>-</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		-							
-											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<div> ☒ None </div> <table border="1"> <tr> <td>Amgen, Novartis, MSD, AZ, NovoNordisk, Bago, Gador, Baliarda, Adium, Nolter, Casasco</td> <td></td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Amgen, Novartis, MSD, AZ, NovoNordisk, Bago, Gador, Baliarda, Adium, Nolter, Casasco							
Amgen, Novartis, MSD, AZ, NovoNordisk, Bago, Gador, Baliarda, Adium, Nolter, Casasco											
6	Payment for expert testimony	<div> ☒ None </div> <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<div> ☒ None </div> <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<div> ☒ None </div> <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	<div> ☒ None </div> <table border="1"> <tr> <td>MSD</td> <td></td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		MSD							
MSD											
ju m p j u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<div> ☒ None </div> <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<div>x None</div> <div></div> <div></div> <div></div>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<div>x None</div> <div></div> <div></div> <div></div>	
13	Other financial or non-financial interests	<div>x None</div> <div></div> <div></div> <div></div>	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Pablo Corral
DNI 23453688

ICMJE DISCLOSURE FORM

Date: 26/10/2026

Your Name: Natalia Nardelli

Manuscript Title: Edición génica in vivo de PCSK9 en la prevención cardiovascular aterosclerótica: de la validación genética a la clínica

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i5.21056>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ ☒ <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☐ <table border="1"> <tr> <td>Sanofi</td> <td>Consulting fees were paid directly to me.</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Sanofi	Consulting fees were paid directly to me.							
Sanofi	Consulting fees were paid directly to me.										
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ <table border="1"> <tr> <td>Novo Nordisk</td> <td>I was paid directly for conference talks and short educational videos.</td> </tr> <tr> <td>Adium; Eurofarma; Gador; Panalab; Silanes; Novartis; Bagó; Siegfried; Roche</td> <td>Honoraria were paid directly to me.</td> </tr> <tr> <td></td> <td></td> </tr> </table>	Novo Nordisk	I was paid directly for conference talks and short educational videos.	Adium; Eurofarma; Gador; Panalab; Silanes; Novartis; Bagó; Siegfried; Roche	Honoraria were paid directly to me.					
Novo Nordisk	I was paid directly for conference talks and short educational videos.										
Adium; Eurofarma; Gador; Panalab; Silanes; Novartis; Bagó; Siegfried; Roche	Honoraria were paid directly to me.										
6	Payment for expert testimony	☒ None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
7	Support for attending meetings and/or travel	☐ <table border="1"> <tr> <td>Novo Nordisk; Adium; Roche; Roemmers; Casasco; Nolter</td> <td>Travel expenses were covered directly by the sponsoring companies.</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Novo Nordisk; Adium; Roche; Roemmers; Casasco; Nolter	Travel expenses were covered directly by the sponsoring companies.							
Novo Nordisk; Adium; Roche; Roemmers; Casasco; Nolter	Travel expenses were covered directly by the sponsoring companies.										
8	Patents planned, issued or pending	☒ None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ <table border="1"> <tr> <td>Sociedad Argentina de Lípidos</td> <td>Treasurer (unpaid).</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Sociedad Argentina de Lípidos	Treasurer (unpaid).							
Sociedad Argentina de Lípidos	Treasurer (unpaid).										

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Natalia Nardelli